dc.contributor.author | Yilmaz N. | |
dc.contributor.author | Can M. | |
dc.contributor.author | Kocakaya D. | |
dc.contributor.author | Karakurt S. | |
dc.contributor.author | Yavuz S. | |
dc.date.accessioned | 2019-08-13T12:10:23Z | |
dc.date.accessioned | 2019-08-13T15:53:09Z | |
dc.date.available | 2019-08-13T12:10:23Z | |
dc.date.available | 2019-08-13T15:53:09Z | |
dc.date.issued | 2014 | |
dc.identifier.issn | 1756-1841 | |
dc.identifier.uri | https://dx.doi.org/10.1111/1756-185X.12399 | |
dc.identifier.uri | http://hdl.handle.net/11446/1846 | |
dc.description | PubMed ID: 24864029 | en_US |
dc.description.abstract | To assess the effect of mycophenolate mofetil (MMF) on pulmonary functions in patients with systemic sclerosis-associated lung disease (SSc-ILD) who experienced an inadequate response to first line cyclophosphamide (CYC) therapy. Twelve consecutive SSc-ILD patients who received MMF due to inadequate response to CYC as a first line agent, were retrospectively reviewed. Over the course of 2 years, pulmonary function tests (PFT) and high-resolution computed tomography (HRCT) scans were performed. Following initial baseline tests, PFTs were continued at a frequency of every 6 months and HRCT scans were performed every 12 months. After MMF treatment, values of forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) improved in three (25%) and two (16.6%) patients, respectively. It is also noted that the evaluation of serial HCRT scans showed no change in 54.5% of patients. Our case series suggested that PFT and imaging scores seemed to be stabilized by MMF in SSc-ILD patients who were inadequate responders to CYC. © 2014 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Blackwell Publishing | en_US |
dc.identifier.doi | 10.1111/1756-185X.12399 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Interstitial lung disease | en_US |
dc.subject | Mycophenolate mofetil | en_US |
dc.subject | Scleroderma | en_US |
dc.title | Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: A case series | en_US |
dc.type | article | en_US |
dc.relation.journal | International Journal of Rheumatic Diseases | en_US |
dc.department | DBÜ | en_US |
dc.identifier.issue | 8 | en_US |
dc.identifier.volume | 17 | en_US |
dc.identifier.startpage | 923 | en_US |
dc.identifier.endpage | 928 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.department-temp | DBÜ | en_US |